Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Advancing Gene Editing, AI & Logic Gating to Develop Safe, Controllable Cell & Gene, mRNA & Microbiome-based Therapies
Welcome to the 3rd Synthetic Biology Based Therapeutics Summit
As biotech propels forward, rewriting the very rules of biological systems for targeted, controlled, and safe therapeutic outcomes grows exponentially.
With advancements in DNA synthesis, tissue engineering, and the emergence of logic gating, the 3rd Synthetic Biology-Based Therapeutics Summit is a platform uniting academia, engineers, and drug developers working towards increased specificity, durability and potency.
Covering all the hottest applications from cell and gene therapy, mRNA based therapies and the microbiome with workshops, panels, case studies and clinical updates, this summit encapsulates the forefront of engineered biology.
Gain valuable insights on synthetic cytokines, gene circuitry, AI-driven protein design, enhanced gene engineering, and the groundbreaking world of engineered biology from our expert speaker faculty spanning the likes of Arsenal Bio, Synlogic, Senti Bio, Replay Bio, BMS, Merck, Kite Pharma, Johns Hopkins, MIT, Strand Therapeutics, and more.
Following explosive developments in engineering capability, the 3rd Synthetic Biology-Based Therapeutics Summit is a platform uniting technology, engineers, and drug developers rewriting the very rules of biological systems for targeted, controlled, and safe therapeutic outcomes.
Join us to explore:
OR and AND Gating with Senti Bio
Next-gen mRNA Transcript Sensor Design with Strand Therapeutics
Cytokine/Anti-cytokine Antibody Fusion Proteins with Merck
AI-Guided DNA Synthesis with Replay Bio
Free Energy Calculation Computational Approach with Stanford
Loss- and gain-of-function augmentation with Arsenal
And many more!
As the divide between academia and industry narrows, this summit acts as a bridge, fostering collaboration and partnerships that can drive your platform or drug development strategy forward.
Explosive Growth: Synthetic biology startups witnessed an investment surge, skyrocketing from $7.8 billion in 2020 to an astonishing $18 billion in 2021, the fruits of their labour are now ripe!
Collaborative Power: The year 2023 has set the stage for unprecedented collaborations, featuring industry giants like Bit.bio, Astellas, Hebecell, BMS, Twist Bio, Replay Bio, and Gilead, all fueling innovation in synthetic biology-based therapeutics.
AI Revolution: In the heart of this transformative era, machine learning and AI have emerged as game-changers. They're enabling the creation of synthesized human proteins, novel protein structures, and T-cell repertoires, paving the way for generating vast libraries to discover new structures at an unprecedented scale!